Succinylacetone – 50 mg

Brand:
Cayman
CAS:
51568-18-4
Storage:
-20
UN-No:
Non-Hazardous - /

Succinylacetone is an inhibitor of δ-aminolevulinic acid dehydratase (Ki = 300 nM for human erythrocyte enzyme).{36832} It inhibits heme biosynthesis and decreases the growth of murine erythroleukemia cells when used at concentrations of 0.1 and 1 mM.{36833} Succinylacetone is an abnormal metabolite of tyrosine that accumulates in hereditary tyrosinemia type I, a disorder characterized by a deficiency in fumarylacetoacetate hydrolase (FAH), the final enzyme in tyrosine catabolism.{36834} Without functional FAH, fumarylacetoacetate is converted into succinylacetone. In a rat model of hypertyrosinemia, succinylacetone (40 mg/kg twice daily) increases levels of δ-aminolevulinic acid in urine, decreases heme levels in liver, kidney, spleen, and vascular tissues, and reduces sensitivity of isolated rat aortic rings to endothelium-dependent and -independent vasodilation. Increased levels of succinylacetone has been used as a marker of tyrosinemia type 1.{36835}  

 

Available on backorder

SKU: 25501 - 50 mg Category:

Description

An inhibitor of δ-aminolevulinic acid dehydratase (Ki = 300 nM); inhibits heme biosynthesis at 0.1 and 1 mM; an abnormal metabolite of tyrosine that accumulates in, and is used as a biomarker for, hereditary tyrosinemia type I; increases levels of δ-aminolevulinic acid in urine, decreases heme levels in liver, kidney, spleen, and vascular tissues, and reduces sensitivity of isolated rat aortic rings to endothelium-dependent and -independent vasodilation at 40 mg/kg twice daily


Formal name: 4,6-dioxo-heptanoic acid

Synonyms:  NSC 174804

Molecular weight: 158.2

CAS: 51568-18-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Cardiovascular System|Blood|Erythrocytes & Hemoglobin||Research Area|Cardiovascular System|Vasculature|Vasoconstriction